Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.

Autor: Séverine Mercier-Delarue, Christine Durier, Nathalie Colin de Verdière, Jean-Dominique Poveda, Vincent Meiffrédy, Maria Dolores Fernandez Garcia, Stéphane Lastère, Raymond Césaire, Jean-Claude Manuggera, Jean-Michel Molina, Ali Amara, François Simon

Publikováno v: PLoS ONE, Vol 12, Iss 5, p e0177882 (2017)

Given the possibility of yellow fever virus reintroduction in epidemiologically receptive geographic areas, the risk of vaccine supply disruption is a serious issue. New strategies to reduce the doses of injected vaccines should be evaluated very car

Externí odkaz: https://doaj.org/article/a4c776ce34ff4abaa89c703ad3c1f5e3

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial

Autor: Antoine Chéret, Rebecca Bauer, Vincent Meiffrédy, Pauline Lopez, Faïza Ajana, Karine Lacombe, Philippe Morlat, Caroline Lascoux, Jacques Reynes, Ruxandra Calin, Sylvie Abel, Cécile Goujard, Christine Rouzioux, Véronique Avettand-Fenoel, Laurence Meyer

Publikováno v: The Journal of antimicrobial chemotherapy. 77(9)

Background Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1 infection (PHI) is unknown. We hypothesized that once-daily dolutegravir/tenofovir/emtricitabine could r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52fa9d2c93ad3984b95b5cb1709cb1a8
https://pubmed.ncbi.nlm.nih.gov/35762503

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype

Autor: Nathalie Colin de Verdière, Christine Durier, Maria Dolores Fernandez Garcia, Raymond Césaire, Jean-Dominique Poveda, Jean-Michel Molina, Ali Amara, François Simon, Vincent Meiffrédy, Séverine Mercier-Delarue, Jean-Claude Manuggera, Stéphane Lastère

Publikováno v: PLoS ONE
PLoS ONE, Public Library of Science, 2017, 12 (5), pp.e0177882. ⟨10.1371/journal.pone.0177882⟩
PLoS ONE, 2017, 12 (5), pp.e0177882. ⟨10.1371/journal.pone.0177882⟩
PLoS ONE, Vol 12, Iss 5, p e0177882 (2017)

International audience; Given the possibility of yellow fever virus reintroduction in epidemiologically receptive geographic areas, the risk of vaccine supply disruption is a serious issue. New strategies to reduce the doses of injected vaccines shou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eaf4522d83f1fc4f004c68dab07d307
https://pubmed.ncbi.nlm.nih.gov/28562615

Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized Study

Autor: Maria Beumont-Mauviel, Cécile Goujard, Raphaelle El Habib, Jean-Pierre Aboulker, Vincent Meiffrédy, Jean-François Delfraissy, Houria Hendel-Chavez, Alain Venet, Yves Levy, Yacine Taoufik, Christine Rouzioux, Marianne Burgard, Fabienne Marcellin

Publikováno v: AIDS Research and Human Retroviruses. 23:1105-1113

HIV-specific T cell responses play a critical role in the control of infection. We evaluated the impact of immune-based interventions in patients first treated during primary HIV-1 infection (PHI). Forty-three patients were randomized within three gr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739f4922284918c0b2ea29efeff4c620
https://doi.org/10.1089/aid.2007.0047